FDA APPROVED...Gazyva (obinutuzumab) for use i... - CLL Support
FDA APPROVED...Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated CLL.
You need to be a member of this community to see this post.
Read more about...
4 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
24 months, compared with patients who received obinutuzumab plus chlorambucil: 88% vs. 64%. Overall...
CALQUENCE gets FDA approval for treating CLL
https://www.biospace.com/article/fda-approves-astrazeneca-s-calquence-in-cll-following-strong-clinic
Venetoclax (ABT-199) Receives Breakthrough Therapy Designation In Relapsed Or Refractory CLL In Previously Treated 17p deletion Patients
and the background on the FDA breakthrough designation, visit our website http://cllsociety.org...
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
analysis of COVID-19 in CLL patients receiving venetoclax-based combinations and CIT as first-line...
Zanubrutinib Bests Bendamustine-Rituximab in Previously Untreated CLL/SLL
kemia/zanubrutinib-bests-bendamustine-rituximab-cll-sll-previously-untreated/